CDH2 and ovarian carcinoma: This lack of metastatic spread of the ovarian cancer cells to the lung following OP treatment is highly dose dependent on the treatment regime, which may be due to in part of a disruptive tumor vasculature development (reduced host CD31+ endothelial cell migration) or result in a decreased expression of the cell surface mesenchymal marker, N-cadherin, and an increased expression of the cell surface epithelial marker, E-cadherin as previously reported by us for pancreatic cancer [22].